Lantern Pharma Announces Positive Clinical Update from Ongoing Phase 2 HARMONIC™ Clinical Trial
Lantern Pharma (NASDAQ: LTRN), an AI-driven cancer therapy developer, announced positive preliminary results from the initial patient group in its ongoing HARMONIC™ phase 2 clinical trial. The trial is evaluating Lantern's drug candidate LP-300, combined with pemetrexed and carboplatin, in never smokers with advanced non-small cell lung cancer (NSCLC) who have progressed after tyrosine kinase inhibitor (TKI) treatment. LP-300, developed using Lantern's AI platform RADR®, showed a predictable safety profile consistent with the chemotherapy regimen alone. Among the seven patients in the initial safety lead-in phase, no dose-limiting toxicities or treatment-related discontinuations were observed. The most common adverse events were decreases in white blood cell and platelet counts.
Lantern Pharma Announces Positive Clinical Update from Ongoing Phase 2 HARMONIC™ Clinical Trial